SomaLogic 的投资者已决定通过投票批准与 Standard BioTools 的交易。 Investors in SomaLogic have decided to approve a deal with Standard BioTools through a vote.

领先的蛋白质组学技术公司 SomaLogic 宣布，其股东已投票批准与生命科学工具提供商 Standard BioTools 的交易。 SomaLogic, a leading proteomics technology company, announced that its stockholders have voted to approve a transaction with Standard BioTools, a provider of life sciences tools. 此次批准是交易完成的一个重要里程碑，该交易旨在打造生命科学工具领域的多元化领导者。 This approval represents a significant milestone towards the completion of the transaction, which aims to create a diversified leader in the life sciences tools sector. 合并后的公司将受益于扩大的规模和更强大的资产负债表，以推动未来的增长。 The combined company will benefit from enhanced scale and a stronger balance sheet to fuel future growth.